regeneron food and drug administration news - Search News

Sanofi, Regeneron and FDA

Investopedia · 1d

Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD

Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary disease received approval from the Food and Drug Administration.

Hosted on MSN · 1d

Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.

Investor's Business Daily on MSN · 1d

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

8h

Regeneron: Long-Term Defensive Investment

Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...

1d

Sanofi blockbuster drug wins clearance in US for lung disease

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

Pharmalittle: We’re reading about a Regeneron biosimilar fight, a ‘positive surprise’ for Biogen lupus drug, and more

A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...

5d

Amgen gets early win in Regeneron lawsuit over Eylea biosimilar

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results